/
•
•
Detailed stories on technology startups, business and economic current affairs.
The Hyderabad-based contract manufacturer has seen its big European bet sour. Can its new CEO move mountains?

Gland Pharma is hurting. A European acquisition, made a little over a year ago, has ended up becoming a millstone around its neck.
The Hyderabad-based injectables maker’s management, eager to put a positive spin on the over Rs 1,000 crore acquisition, continues to insist that Cenexi, the French contract drug manufacturer, is a good addition and profits are just around the corner. “At Cenexi, a beta-level breakeven will happen in Q4 [of 2024-25],” said Ravi Mitra, chief financial officer of Gland Pharma, in an investor call following the release of the July-September quarter results.
But then, a similar optimistic prognosis …